Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE for Leg Ulcers in Sickle Cell Disease
NCT02600390Phase 2Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of Sanguinate in sickle cell disease (SCD), sponsored by Prolong Pharmaceuticals. Started Mar 2016; status: completed.
02
Drugs
Sanguinate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02600390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600390.